Recent clinical trials in phase III are only including HER2 (human epidermal growth factor receptor 2)/neu targeting breast cancer21; tyrosinase, gp100 antigen, and MART‐1 (melanoma antigen recognized by T cells 1) antigen targeting melanoma; PR3 (proteinase‐3) targeting leukaemia.22 Here, PRTN3 is linked to melanoma.